Methylphenidate ELISA Kit

Name: Methylphenidate ELISA Kit
SKU: DEIA-XYZ210
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Urine, Blood, Oral Fluid, Forensic Matrices

Species Reactivity

Human; Research Animal

Detection Method

cELISA

Intended Use

For the determination of trace quantities of Methylphenidate/Ritalinic Acid and/or other metabolites in human urine, blood, oral fluid.

Contents of Kit

1.EIA Buffer
2.Wash Buffer Concentrate (10X)
3.K-Blue Substrate
4.Drug-Enzyme Conjugate
5.Antibody Coated Plate
6.Acid Stop Solution
7.Qualitative QC Positive Control
8.Qualitative QC Negative Control

Storage

This kit can be used until the expiration date on the label when stored refrigerated at 2-8°C. Note: This kit requires controls to be stored frozen IMMEDIATELY upon receipt. Reference kit label for details.

Sensitivity

General Description

CD's Methylphenidate/Ritalinic Acid ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS).

Standard Curve

Citations

Have you cited DEIA-XYZ210 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Quantum Spatial Modulation of Optical Channels: Quantum Boosting in Spectral Efficiency

IEEE COMMUNICATIONS LETTERS

Authors: Gulbahar, Burhan; Memisoglu, Gorkem

Abstract

Spatial modulation (SM) improves spectral efficiency (SE) by creating the constellation of active optical antenna indices. However, quantum properties of light are not exploited to improve the SE. In this letter, multi-plane diffraction (MPD) set-up creating exponentially increasing number of propagation paths for classical sources is exploited to introduce quantum spatial modulation (QSM). Exponential number of paths and quantum superposition-based classical symbol generation for transmitting simultaneous multiple classical symbols are exploited for linear and exponential quantum boosting of SM, respectively. It is theoretically modeled, numerically analyzed, and the challenges of joint design of source-channel coding and QSM are discussed.

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

BONE MARROW TRANSPLANTATION

Authors: Shah, Mithun Vinod; Saliba, Rima M.; Rondon, Gabriela; Chen, Julianne; Soebbing, Doris; Rus, Ioana; Alousi, Amin; Oran, Betul; Kebriaei, Partow; Qazilbash, Muzaffar; Parmar, Simrit; Hosing, Chitra; Khouri, Issa F.; Popat, Uday R.; Champlin, Richard E.; Ciurea, Stefan O.

Abstract

6 Allogeneic SCT for older patients remains challenging at least in part due to graft-versus-host disease (GVHD) and higher non-relapse mortality (NRM). We conducted a prospective pilot study primarily for older patients undergoing matched unrelated donor (MUD) SCT using a reduced-intensity (RIC) melphalan-based conditioning and post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis with tacrolimus and mycophenolate mofetil. Twenty-two patients (median age 64, IQR 58, 66) underwent RIC MUD SCT for high-risk hematological malignancies including AML/MDS (73%), CML/MPD (18%), and other (10%). Two (9%) patients had early death; the rest (100%) engrafted. After a median follow-up of 17 months, 11 patients were alive and disease-free with an estimated 2-year progression-free (PFS) and overall (OS) survival of 48%. The cumulative incidences of grades 2-4 and 3-4 acute GVHD (aGVHD) at day + 100 and 2-years were 32 and 4%, and 59 and 24%, respectively. No cases of chronic GVHD (cGVHD) were noted. However, late acute GVHD was observed in 6 (27%) patients. In conclusion, RIC MUD SCT with melphalan-based conditioning and PTCy-based GVHD-based prophylaxis for older patients appears effective in controlling relapse. While cGVHD was not seen and early aGVHD appears controllable, a significant proportion developed late aGVHD responsible for higher NRM seen in these patients.